These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11724839)

  • 1. Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda.
    Mracna M; Becker-Pergola G; Dileanis J; Guay LA; Cunningham S; Jackson JB; Eshleman SH
    J Clin Microbiol; 2001 Dec; 39(12):4323-7. PubMed ID: 11724839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of the applied biosystems ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in pediatric plasma samples.
    Cunningham S; Ank B; Lewis D; Lu W; Wantman M; Dileanis JA; Jackson JB; Palumbo P; Krogstad P; Eshleman SH
    J Clin Microbiol; 2001 Apr; 39(4):1254-7. PubMed ID: 11283037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains.
    Eshleman SH; Hackett J; Swanson P; Cunningham SP; Drews B; Brennan C; Devare SG; Zekeng L; Kaptué L; Marlowe N
    J Clin Microbiol; 2004 Jun; 42(6):2711-7. PubMed ID: 15184457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D.
    Church JD; Jones D; Flys T; Hoover D; Marlowe N; Chen S; Shi C; Eshleman JR; Guay LA; Jackson JB; Kumwenda N; Taha TE; Eshleman SH
    J Mol Diagn; 2006 Sep; 8(4):430-2; quiz 527. PubMed ID: 16931582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of two commercially available sequence-based HIV-1 genotyping systems for the detection of drug resistance against HIV type 1 group M subtypes.
    Beddows S; Galpin S; Kazmi SH; Ashraf A; Johargy A; Frater AJ; White N; Braganza R; Clarke J; McClure M; Weber JN
    J Med Virol; 2003 Jul; 70(3):337-42. PubMed ID: 12766994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.
    Eshleman SH; Guay LA; Mwatha A; Cunningham SP; Brown ER; Musoke P; Mmiro F; Jackson JB
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):595-9. PubMed ID: 15242535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012).
    Eshleman SH; Guay LA; Mwatha A; Brown ER; Cunningham SP; Musoke P; Mmiro F; Jackson JB
    J Acquir Immune Defic Syndr; 2004 Feb; 35(2):126-30. PubMed ID: 14722443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer.
    Eshleman SH; Crutcher G; Petrauskene O; Kunstman K; Cunningham SP; Trevino C; Davis C; Kennedy J; Fairman J; Foley B; Kop J
    J Clin Microbiol; 2005 Feb; 43(2):813-7. PubMed ID: 15695685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants.
    Church JD; Huang W; Parkin N; Marlowe N; Guay LA; Omer SB; Musoke P; Jackson JB; Eshleman SH
    AIDS Res Hum Retroviruses; 2009 Jul; 25(7):657-63. PubMed ID: 19621988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults.
    Becker-Pergola G; Kataaha P; Johnston-Dow L; Fung S; Jackson JB; Eshleman SH
    AIDS Res Hum Retroviruses; 2000 May; 16(8):807-13. PubMed ID: 10826487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic.
    Charpentier C; Gody JC; Tisserand P; Matta M; Péré H; Fournier J; Mbitikon O; Bélec L
    Antivir Ther; 2011; 16(8):1347-50. PubMed ID: 22155917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping.
    Chen JH; Wong KH; Chan K; Lam HY; Lee SS; Li P; Lee MP; Tsang DN; Zheng BJ; Yuen KY; Yam WC
    J Clin Virol; 2007 Jun; 39(2):125-31. PubMed ID: 17449318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon.
    Turriziani O; Russo G; Lichtner M; Stano A; Tsague G; Maida P; Vullo V; Antonelli G
    AIDS Res Hum Retroviruses; 2008 Jun; 24(6):781-5. PubMed ID: 18507527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).
    Eshleman SH; Becker-Pergola G; Deseyve M; Guay LA; Mracna M; Fleming T; Cunningham S; Musoke P; Mmiro F; Jackson JB
    J Infect Dis; 2001 Oct; 184(7):914-7. PubMed ID: 11509999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus type 1 drug resistance testing: a comparison of three sequence-based methods.
    Erali M; Page S; Reimer LG; Hillyard DR
    J Clin Microbiol; 2001 Jun; 39(6):2157-65. PubMed ID: 11376051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda.
    Troyer RM; Lalonde MS; Fraundorf E; Demers KR; Kyeyune F; Mugyenyi P; Syed A; Whalen CC; Bajunirwe F; Arts EJ
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):235-50. PubMed ID: 18284323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance characteristics of human immunodeficiency virus type 1 (HIV-1) genotyping systems in sequence-based analysis of subtypes other than HIV-1 subtype B.
    Jagodzinski LL; Cooley JD; Weber M; Michael NL
    J Clin Microbiol; 2003 Mar; 41(3):998-1003. PubMed ID: 12624021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presence of multiple genetic subtypes of human immunodeficiency virus type 1 proviruses in Uganda.
    Bruce C; Clegg C; Featherstone A; Smith J; Biryahawaho B; Downing R; Oram J
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1543-50. PubMed ID: 7888209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
    Kurle SN; Gangakhedkar RR; Sen S; Hayatnagarkar SS; Tripathy SP; Paranjape RS
    AIDS Res Hum Retroviruses; 2007 May; 23(5):682-5. PubMed ID: 17530993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.